Injury guide

Dupixent and skin T-cell cancer

Skin T-cell cancer can look like eczema. Ask your skin doctor about a rash that changes or persists, and keep your test and drug records.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 20269 sources

This may apply to you if

  • These suggestions help you prepare for a claim check. They are not a firm's acceptance rules.
  • For preparation: note Dupixent use, the reason it was prescribed and the diagnosis you want checked. This does not decide whether a lawyer will accept the case.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Jenna Mandel · Thomas Jefferson University · Lead author, Dermatology and Cutaneous Biology

Finding: The matched record-based eczema cohort found more CTCL diagnoses after dupilumab exposure; it does not establish individual causation.

Mandel et al: CTCL after dupilumab, 2024 (opens in a new tab) · Aug 14, 2024 · Checked Oct 3, 2026

The evidence and its limits

Thomas Jefferson University · Dermatologic Therapy · 2024

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis

Design:
Cohort
Participants:
19,612 dupilumab-treated patients and 19,612 matched patients without dupilumab.
Finding:
More CTCL diagnoses were recorded in the exposed eczema cohort.
Main limitation
Retrospective billing records and limited matching; earlier missed CTCL may be unmasked. Association does not prove individual cause.

Read the source: Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis (opens in a new tab) · Checked Oct 3, 2026

Memorial Sloan Kettering Cancer Center · Journal of the European Academy of Dermatology and Venereology · 2024

Cutaneous T-cell lymphoma and dupilumab use: matched outcomes

Design:
Cohort
Participants:
27 lymphoma patients with prior dupilumab and 27 matched lymphoma patients without it.
Finding:
No detected difference in survival or treatment outcomes.
Main limitation
Small selected cancer-center sample and limited follow-up; no causality or incidence analysis. Published online2024, issue2025.

Read the source: Cutaneous T-cell lymphoma and dupilumab use: matched outcomes (opens in a new tab) · Checked Oct 3, 2026

The short answer

What is skin T-cell cancer?
CTCL means a type of cancer in skin immune cells. Some forms can look like eczema. A rash alone does not show that you have cancer. [9]
What signs should I discuss with a doctor?
Ask your doctor about a rash that lasts or changes. Two forms of this cancer can cause red patches, raised spots or skin lumps. [9]
How is this cancer diagnosed and treated?
A doctor may take a skin sample to check for cancer cells. This test is a biopsy. More than one sample may be needed. [9]
What does the research say about Dupixent?
A study found more skin T-cell cancer diagnoses in people treated with Dupixent. It cannot show what caused one person's cancer. [5]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

When it fits this case

  • These suggestions help you prepare for a claim check. They are not a firm's acceptance rules.
  • For preparation: note Dupixent use, the reason it was prescribed and the diagnosis you want checked. This does not decide whether a lawyer will accept the case.

What is skin T-cell cancer?

CTCL means a type of cancer in skin immune cells. Some forms can look like eczema. A rash alone does not show that you have cancer.

What signs should I discuss with a doctor?

Ask your doctor about a rash that lasts or changes. Two forms of this cancer can cause red patches, raised spots or skin lumps.

The National Cancer Institute describes how early skin cancer can be hard to tell from eczema. Ask which diagnosis fits your skin changes rather than trying to name the disease from a photo.

Bring notes on which areas changed before and after each treatment. Follow your prescriber's drug instructions; a legal claim is not a plan for changing medicine.

How is this cancer diagnosed and treated?

A doctor may take a skin sample to check for cancer cells. This test is a biopsy. More than one sample may be needed.

Skin and blood tests help doctors diagnose the two forms described by the National Cancer Institute. Treatment choices depend on the disease stage and your health. Ask the care team what your own report means.

What does the research say about Dupixent?

A study found more skin T-cell cancer diagnoses in people treated with Dupixent. It cannot show what caused one person's cancer.

The 2024 record study compared 19,612 treated eczema patients with 19,612 matched patients who were not treated. Errors in billing codes and cancer that first looked like eczema can affect its findings.

A separate study compared 27 cancer patients who had used the drug with 27 matched cancer patients who had not. It found no clear difference in survival or treatment outcomes. This small study was not a test of how often the drug causes cancer.

Does this diagnosis qualify for a claim?

The June 2026 transfer order describes claims about this cancer after Dupixent use. It did not decide that the drug caused the cancer.

The federal case group is MDL 3180. That means separate cases share pretrial work. A lawyer still needs to check your actual diagnosis, drug dates and the law that applies to your claim.

Do not treat a study's follow-up period as a filing rule. Ask for a time-limit check using your dates of care, diagnosis and place of treatment.

What records could help explain my history?

Save your skin test reports and Dupixent dates. Ask the provider about missing records. A medical diagnosis and a legal claim are separate checks.

As a preparation step, list the first rash date, earlier diagnoses and changes during treatment. Keep the full tissue report if you have it, not just a note that says a test was positive.

The federal health-record access rule has limits, including an exception for psychotherapy notes. Ask the office what it can provide and how to request it.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. Dupixent JPML transfer order, June 4, 2026Dupixent JPML transfer order, June 4, 2026 · court
  5. Mandel et al: CTCL after dupilumab, 2024Mandel et al: CTCL after dupilumab, 2024 · study
  6. Stuver et al: matched CTCL outcomes, 2024 online/2025 issueStuver et al: matched CTCL outcomes, 2024 online/2025 issue · study
  7. FDA potential-signal table, information as of March 6, 2025FDA potential-signal table, information as of March 6, 2025 · regulator
  8. MedlinePlus: dupilumab injection, revised August 15, 2025MedlinePlus: dupilumab injection, revised August 15, 2025 · regulator
  9. NCI patient guide: two common forms of skin T-cell cancer

Checked against 9 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026